#2147
Nutritional Assessment and Vitamin Deficiencies in Patients with NETs
Introduction:
As a result of disease or related to its management, patients with neuroendocrine tumours may have altered gut or pancreatic function that can cause nutritional deficiencies.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Lim S,
Reynolds M,
Rees D,
Chaudhry R,
Blackhouse J,
Keywords:
Nutrition,
Dietetics,
Malnutrition,
Vitamin Deficiency,
Screening,
#1245
Identification of Response Predictors to Temozolomide-Based Chemotherapy
Introduction:
Capecitabine and temozolomide are active in the treatment of metastatic pNETs, with response rates ranging from 30% to 70%. Several small retrospective series have suggested that MGMT deficiency may predict response to temozolomide, however expression of MGMT has not been validated as a predictive biomarker. Cytotoxic chemotherapy is thought to be most active in aggressive tumors, however the ki-67 index has not been formally evaluated as a predictive factor. It is unclear whether chromosomal instability (which correlates with alternate lengthening of telomeres) predicts response.
Conference:
12th Annual ENETSConcerence (2015)
Presenting Author:
Strosberg J
Authors:
Strosberg J,
Cives M,
Brelsford M,
Black M,
Meeker A,
Keywords:
ki67,
MGMT,
ALT,
chromosomal instability,
temozolomide,
capecitabine,
pNET,
#318
The SEER as a Prophet: Epidemiological Analysis as a Harbinger of Evolving Priorities in Gastroenteropancreatic Neuroendocrine Neoplasia
Introduction:
Previous epidemiology analysis of tumor registries established that gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs) were both more prevalent, and more malignant, than previously recognized.
Conference:
8th Annual ENETSConcerence (2011)
Presenting Author:
Authors:
Lawrence B,
Gustafsson B,
Chan A,
Svejda B,
Kidd M,
Keywords:
black,
carcinoids,
epidemiology,
GEP-NET,
incidence,
pancreas,
rectal,
SEER,
survival,
USA,
